
jan pm et
summari compani global research-bas pharmaceut busi key drug
humira rheumatoid arthriti indic
price-to-earnings oper ep
heavili reliant one drug humira
current account sale howev
recently-approv drug help diversifi sale
fiscal year end dec ep estim base cfra
oper earn histor earn report
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
stk
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
see sale grow
see humira sale
aid
greater penetr emerg market
see imbruvica co-promot johnson
johnson sale
see hepat
sale primarili mavyret
august fda approv mavyret
treat six genotyp hepat
eight week price mavyret
per treatment compet therapi
septemb file nda
elagolix treat endometriosi elagolix also
phase test uterin fibroid
septemb enter
non-exclus licens deal amgen
regard humira licens period begin
januari octob
eu humira litig
compani dismiss
pay royalti june
acquir stemcentrx plu
earnout may acquir
pharmacycl whose imbruvica
approv treat three type blood cancer
see ep aid lower
effect tax rate
think share attract valu
trade ep estim
peer outlin long-term object
see sale rise billion
double-digit ep growth
plan launch new
product indic
think oper margin could exceed
think goal impress
aggress particularli new product
launch although humira patent expir
decemb confid
patent surround humira
number patent includ
formul manufactur method
treatment abl protect
biosimilar challeng least
recent humira licens deal
remov overhang share
view biosimilar amjevita
approv fda
risk includ pipelin failur face
target base
slightli peer ep
estim faster growth favor
view pipelin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview abbvi inc global research-bas drug busi emerg separ
compani follow spin-off abbott sharehold share-for-shar
basi januari
key product humira inject biolog tnf tumor necrosi factor blocker treatment
rheumatoid arthriti ra similar condit estim humira account half
global prescript drug market rheumatoid arthriti besid moder sever ra adult
humira also approv mani use includ juvenil idiopath arthriti psoriasi ankylos
spondyl ulcer coliti crohn diseas axial spondyloarthr
humira composit matter patent expir end equival european union
patent set expir eu countri april competitor rheumatoid arthriti market
includ remicad market johnson johnson simponi johnson johnson enbrel
corpor strategi strateg object includ expand humira sale greater
penetr emerg market increas emphasi earlier diagnosi autoimmun patient
new indic also plan launch five signific new product time frame
pipelin pipelin compound indic phase ii phase
oncolog multipl sclerosi well parkinson alzheim diseas decemb fda
approv viekira pak treat hepat plan launch includ levodopa-carbidopa intestin
gel lcig advanc parkinson diseas elotuzumab human monoclon antibodi
treatment multipl myeloma daclizumab monoclon antibodi treatment multipl
sclerosi abt- next-gener inhibitor develop chronic lymphocyt leukemia
new indic humira
phase clinic program includ atrasentan diabet kidney diseas chronic
lymphocyt leukemia cll import program plan phase iib start elagolix uterin
fibroid work partner inhibitor rheumatoid arthriti ra ra
acut kidney injuri associ major cardiac surgeri also intend present clinic
data key develop program includ rapidli advanc hcv program oncolog renal diseas
immunolog alzheim diseas
chairman board
extern affair
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
bullish sinc octob technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
biosimilar drug approv set
exclus brand drug maker see
biosimilar advanc modest rate
next sever year march fda
approv novarti filgrastim biosimilar
sandoz began sell biosimilar
name zarxio septemb april
fda approv inflectra manufactur
celltrion co-market inflectra
biosimilar johnson johnson
remicad began ship inflectra
risk novemb discount
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug note prescript
benefit manag health insur
exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 year date
septemb biotech index
rose vs rise
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci
anticip limit sale growth
mainli due forecast
sale declin
robust growth period
compound annual growth rate think
sale growth somewhat limit
heighten focu high drug price
encourag view strong period
report late-stag clinic
result accommod fda
approv howev fda approv
new drug significantli
robust new drug approv
sinc record approv
think mani newly-approv drug
signific commerci prospect repres
major advanc therapi diseas
cystic fibrosi hepat multipl
sclerosi cancer expect wider
adopt biomark research
genetic-target clinic studi help
late fda introduc
speed develop promis program
expect favor merger acquisit
climat larg pharmaceut firm move
off-set lost revenu expir drug patent
larg biotech bolster drug pipelin
scale acquisit
industri bellweth becam first
biotech compani initi regular dividend
began dividend payment
establish fda author govern
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et capit iq keep buy opinion share inc
keep target in-lin peer
ep estim set ep ep vs
ahead estim sale growth forecast
partli lower viekira sale howev humira sale rose robust spite
sale shortfal believ robust pipelin drive futur growth
also see continu robust humira sale think sever year
biosimilar amjevita reach market amid patent lawsuit
guid ep /jeffrey loo cfa
inc keep target in-lin
peer forward ep estim ep vs
ahead estim lower ep
estim provid preliminari
guidanc low doubl digit sale growth ep growth sale
rose humira humira sale slightli forecast
softer oversea sale indic believ indirect
competit inflectra biosimilar remicad impact
analyst research note compani news
et cfra reiter buy opinion share inc
rais target peer
ep estim faster growth set
ep ep vs ahead view sale
rose humira sale imbruvica rose consist
 sale profit share encourag
result view strong pipelin guid sale
ep midpoint partli aid tax
reform see effect tax rate
rais target in-lin peer
forward ep estim ep vs
ahead view rais ep estim provid
ep guidanc line view sale grew
humira sale imbruvica expect humira sale
approach believ achiev follow patent
settlement also encourag pipelin develop
recent nda file elagolix endometriosi /jeffrey loo cfa
rais target in-lin peer
forward ep estim announc deal
regard humira litig term agreement
grant non-exclus licens humira intellectu properti
licens period begin jan oct
eu humira litig compani dismiss
pay royalti view deal posit remov
overhang world best sell drug /jeffrey loo cfa
rais target slightli peer
forward ep ep vs ahead
estim keep ep estim rais
sale rose global humira sale
 imbruvica sale rose view
pipelin posit await phase data risankizumab
psoriasi upadacitinib rheumatoid arthriti see potenti nda
file compound expect data sever trial
/jeffrey loo cfa
keep target slightli peer
ep estim ep vs in-lin
estim sale rose rise humira sale sale
intern sale imbruvica sale rose strong uptak
first line chronic lymphocyt leukemia think imbruvica gain
market share look continu robust sale imbruvica see
approv addit indic also plan submit nda
elagolix treat endometriosi later year /jeffrey loo cfa
et capit iq add total return
portfolio see among fastest grow
biotech compani although humira composit matter patent expir
dec believ numer patent abl protect
biosimilar competit trade ep estim
think share under-valued target ep
estim pay annual dividend
increas everi year sinc share yield
replac total return model portfolio
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
